Clinical trial preparations for the next pandemic.


Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 11 2020
revised: 13 01 2021
accepted: 20 01 2021
pubmed: 31 1 2021
medline: 15 4 2021
entrez: 30 1 2021
Statut: ppublish

Résumé

This paper describes the need to prepare for the development of antiviral therapeutics for the next pandemic. Preparation would consist of a stockpiling of best practices for clinical trial design, analysis and operations during the current SARS-CoV-2 pandemic as well as continuous development of treatments and methodology between pandemics. This development would be facilitated by a global clinical trial pandemic reserve similar to the military reserves consisting of medical and quantitative methods professionals who would remain engaged between pandemics. Continuous identification of potential antiviral drugs and diagnostic methods would also be needed. Specific methodology addressed includes the importance of large simple trials, follow up time, efficacy endpoint, appropriate estimands, non-inferiority trials, more sophisticated patient accrual models and procedures for data sharing between clinical trials.

Identifiants

pubmed: 33515783
pii: S1551-7144(21)00028-8
doi: 10.1016/j.cct.2021.106292
pmc: PMC7985296
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106292

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Clin Trials. 2012 Dec;9(6):705-13
pubmed: 22684241
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
J Clin Epidemiol. 2017 Nov;91:38-46
pubmed: 28912004
Ther Innov Regul Sci. 2020 Mar;54(2):324-341
pubmed: 32072573
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Trials. 2020 Jun 19;21(1):544
pubmed: 32560744
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
N Engl J Med. 1993 Nov 25;329(22):1615-22
pubmed: 8232430
Stat Biopharm Res. 2020 Jul 6;12(4):399-411
pubmed: 34191971
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Biometrics. 2016 Mar;72(1):215-21
pubmed: 26302239
Lancet. 2008 Oct 4;372(9645):1223-30
pubmed: 18757090
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Stat Biopharm Res. 2020 Jul 29;12(4):483-497
pubmed: 34191981
Biometrics. 1990 Dec;46(4):1171-8
pubmed: 2085632
Ann Intern Med. 2020 Oct 20;173(8):632-637
pubmed: 32634024
Stat Med. 2014 Dec 30;33(30):5265-79
pubmed: 25213096
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440

Auteurs

Jay Herson (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jay.herson@earthlink.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH